Almost a decade after their discovery, the Hafler group described first a functional defect of peripheral CD4+CD25+ Tregs in patients with relapsing-remitting MS [13] that was followed by several reports confirming these observations in MS patients [14, 15]. This evidence concerns the gene CD4 and myeloid sarcoma.